Chronic myeloid leukemia, version 2.2021: NCCN Clinical Practice Guidelines in Oncology Guidelines
| Authors: | Deininger, M. W.; Shah, N. P.; Altman, J. K.; Berman, E.; Bhatia, R.; Bhatnagar, B.; DeAngelo, D. J.; Gotlib, J.; Hobbs, G.; Maness, L.; Mead, M.; Metheny, L.; Mohan, S.; Moore, J. O.; Naqvi, K.; Oehler, V.; Pallera, A. M.; Patnaik, M.; Pratz, K.; Pusic, I.; Rose, M. G.; Smith, B. D.; Snyder, D. S.; Sweet, K. L.; Talpaz, M.; Thompson, J.; Yang, D. T.; Gregory, K. M.; Sundar, H. |
| Title: | Chronic myeloid leukemia, version 2.2021: NCCN Clinical Practice Guidelines in Oncology |
| Abstract: | Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome (Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t(9;22] that gives rise to a BCR-ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase. Tyrosine kinase inhibitor therapy is a highly effective first-line treatment option for all patients with newly diagnosed chronic phase CML. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with chronic phase CML. © 2020 Harborside Press. All rights reserved. |
| Journal Title: | Journal of the National Comprehensive Cancer Network |
| Volume: | 18 |
| Issue: | 10 |
| ISSN: | 1540-1405 |
| Publisher: | Harborside Press |
| Date Published: | 2020-10-01 |
| Start Page: | 1385 |
| End Page: | 1415 |
| Language: | English |
| DOI: | 10.6004/jnccn.2020.0047 |
| PUBMED: | 33022644 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Review -- Export Date: 2 November 2020 -- Source: Scopus |
